Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1414-1420

  Chan, Siu Hong ^a   Cheung, Florence M F ^a   Ng, Wai Tong ^a   Choi, Cheuk Wai ^b   Cheung, Kin Nam ^a   Yiu, Kwan Ho ^a   Lee, Anne W M ^a  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ERCC1; Nasopharyngeal carcinoma; Predictive; Prognosis

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY RESPONSE; CIS-PLATIN; CLINICAL OUTCOME; COMPLEMENTATION; CONFIDENCE INTERVAL; ERCC1; EXCISION REPAIR; FAILURE-FREE RATES; FAILURE-FREE SURVIVAL; IMMUNOSTAINING; LOCOREGIONAL CONTROL; MULTI VARIATE ANALYSIS; NASOPHARYNGEAL CARCINOMA; OVERALL SURVIVAL; PREDICTIVE; PROGNOSIS; PROGNOSTIC FACTORS; RADIOTHERAPY ALONE; STATISTICAL SIGNIFICANCE;

CHEMOTHERAPY; MULTIVARIANT ANALYSIS; PLATINUM COMPOUNDS; RADIATION DAMAGE; TUMORS;

QUALITY ASSURANCE;

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; YOUNG ADULT;

EID: 79952694711     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.12.072     Document Type: Article

References (29)

1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317. (Pubitemid 28175745)
2. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-637.
3. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966-6975.
4. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738. (Pubitemid 46190268)
5. Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 2005;61:1107-1116. (Pubitemid 40340904)
6. Lee AW, Ng WT, Hung WM, et al. Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patientand treatment-related risk factors. Int J Radiat Oncol Biol Phys 2009;73:1121-1128.
7. Chan SH, Ng WT, Kam KL, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: A longitudinal analysis. Int J Radiat Oncol Biol Phys 2009;73:1335-1342.
8. Siddik ZH. Cisplatin resistance, molecular basis of a multi-faceted impediment. In: Teicher B, editor. Cancer drug discovery and development: Cancer drug resistance. Totowa, NJ: Humana Press; 2006. p. 283-307.
9. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
10. Darcy KM, Tian C, Reed E. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 2007;67:4474-4481. (Pubitemid 46815098)
11. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-509. (Pubitemid 46359630)
12. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-354. (Pubitemid 39037082)
13. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008;44:54-60. (Pubitemid 350256935)
14. Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;66:1022-1030. (Pubitemid 44633517)
15. Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:142-151. (Pubitemid 44175659)
16. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cellfree Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-1191. (Pubitemid 29136244)
17. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60:6878-6881. (Pubitemid 32059157)
18. Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003;98:288-291. (Pubitemid 36828452)
19. Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:11-20. (Pubitemid 38501502)
20. Sargent RG, Meservy JL, Perkins BD, et al. Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res 2000;28:3771-3778.
21. De Silva IU, McHugh PJ, Clingen PH, et al. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-7990.
22. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-5787. (Pubitemid 38787963)
23. McMillan TJ, Steel GG. DNA damage and cell killing. In: Steel GG, editor. Basic clinical radiobiology. 3rd ed. London: Hodder Arnold; 2002. p. 71-83.
24. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 2008;28:5082-5092.
25. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:3855-3859. (Pubitemid 47037591)
26. Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009;20:1414-1419.
27. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer 2009;64:131-139.
28. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-6217. (Pubitemid 41262950)
29. Ma BB, Hui EP, Wong SC, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma - Correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 2009;20:1854-1859.